Results 41 to 50 of about 473,693 (291)

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2

Frontiers in Immunology, 2022
BackgroundHeterologous vaccinations against SARS-CoV-2 with ChAdOx1 nCoV-19 and a second dose of an mRNA-based vaccine have been shown to be more immunogenic than homologous ChAdOx1 nCoV-19.
Robert Markewitz, David Juhl, Daniela Pauli, Siegfried Görg, Ralf Junker, Jan Rupp, Sarah Engel, Katja Steinhagen, Victor Herbst, Dorinja Zapf, Christina Krüger, Christian Brockmann, Frank Leypoldt, Justina Dargvainiene, Benjamin Schomburg, Shahpour Sharifzadeh, Lukas Salek Nejad, Klaus-Peter Wandinger, Malte Ziemann   +18 more
doaj   +1 more source

Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines

, 2023
Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector&ndash ...
Verena Haselmann, Michael Neumaier, Maximilian Kittel, Margot Thiaucourt, Catharina Gerhards, Michael Hetjens   +5 more
core   +1 more source

Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants.

PLoS ONE, 2023
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 and caused the coronavirus disease 2019 (COVID-19) pandemic worldwide. As of September 2023, the number of confirmed coronavirus cases has reached over 770 million and caused ...
Se Eun Kim, So Hee Park, Woo-Jung Park, Gayeong Kim, Seo Yeon Kim, Hyeran Won, Yun-Ho Hwang, Heeji Lim, Hyeon Guk Kim, You-Jin Kim, Dokeun Kim, Jung-Ah Lee   +11 more
doaj   +1 more source

Reactogenicity and Humoral Immune Response after Heterologous Vaxzevria/Comirnaty Vaccination in a Group of Individuals Vaccinated in the AOU Policlinic “G. Martino” (Messina, Italy): A Retrospective Cohort Study

Vaccines, 2022
On 11 June 2021, the Italian Ministry of Health authorized the heterologous vaccination schedule. The goals of our retrospective study were to (a) evaluate the undesirable effects after the administration of Vaxzevria and Comirnaty vaccines; (b) evaluate
Roberto Venuto, Ioselita Giunta, Mario Vaccaro, Vincenza La Fauci, Concetta Ceccio, Francesco Fedele, Antonino Privitera, Federica Denaro, Giuseppe Pantò, Rosaria Cortese, Giovanna Visalli, Smeralda D’Amato, Andrea Squeri, Raffaele Squeri, Cristina Genovese   +14 more
doaj   +1 more source

Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report

, 2023
Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce.
Parichat Uea-Areewongsa, Boonjing Siripaitoon, Nawamin Pinpathomrat, Siriporn Juthong, Jomkwan Ongarj, Porntip Intapiboon, Juthong, Siriporn, Ongarj, Jomkwan, Siripaitoon, Boonjing, Pinpathomrat, Nawamin, Intapiboon, Porntip, Uea-Areewongsa, Parichat   +11 more
core   +1 more source

H5N1 Protection by Seasonal Influenza Vaccine in Homologous and Heterologous Prime/Boost Vaccination

Journal of Vaccines & Vaccination, 2015
Background A number of different approaches aimed at broadening the cross-protective ability of seasonal influenza vaccines are being explored today. Priming a seasonal vaccine with three administrations of DNA encoding H1 HA corresponding to the HA in the seasonal vaccine has been shown to confer protection against heterologous H1N1 influenza.
Roos A, Roozendaal R
openaire   +1 more source

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination

, 2023
With concerns about the efficacy of repeat annual influenza vaccination, it is important to better understand the impact of priming vaccine immunity and develop an effective vaccination strategy. Here, we determined the impact of heterologous prime-boost
Ki-Hye Kim, Sakinah Muhammad-Worsham, Phillip Grovenstein, Bo Ryoung Park, Noopur Bhatnagar, Rong Liu, Sang-Moo Kang, Bao-Zhong Wang, Jeeva Subbiah   +8 more
core   +1 more source

Choosing between Homologous or Heterologous COVID-19 Vaccination Regimens: A Cross-Sectional Study among the General Population in Italy [PDF]

, 2022
A shortage of COVID-19 vaccines and reports of side-effects led several countries to recommend a heterologous regimen for second vaccine doses. This study aimed to describe the reasons behind individuals’ choices of a homologous or a heterologous ...
Valerio Dimonte, Elena Casabona, Marco Clari, Albanesi, B., Rosanna Irene Comoretto, Alessio Conti, Godono, A., Dimonte, V., Clari, M., Alessandro Godono, Mansour, I., Casabona, E., Comoretto, R. I., Beatrice Albanesi, Ihab Mansour, Ciocan, C., Catalina Ciocan, Conti, A.   +17 more
core   +1 more source

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Emerging Microbes and Infections, 2022
The emerging new VOC B.1.1.529 (Omicron) variant has raised serious concerns due to multiple mutations, reported significant immune escape, and unprecedented rapid spreading speed.
Jingwen Ai, Haocheng Zhang, Yi Zhang, Ke Lin, Yanliang Zhang, Jing Wu, Yanming Wan, Yanfang Huang, Jieyu Song, Zhangfan Fu, Hongyu Wang, Jingxin Guo, Ning Jiang, Mingxiang Fan, Yang Zhou, Yuanhan Zhao, Qiran Zhang, Qiang Liu, Jing Lv, Peiyao Li, Chao Qiu, Wenhong Zhang   +21 more
doaj   +1 more source

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART

, 2022
Data on COVID-19 boosting vaccination in people living with HIV (PLWH) are scant. We investigated the immunogenicity and safety of the BNT162b2 homologous boosting vaccination.
Gianserra, Laura, Fulvia Pimpinelli, Buonomini, Anna Rita, Eugenia Giuliani, Laura Gianserra, Giuliani, Massimo, Aldo Morrone, Pontone, Martina, Christof Stingone, Giuliani, Eugenia, Stingone, Christof, Maria Gabriella Donà, Martina Pontone, Alessandra Latini, Pimpinelli, Fulvia, Donà, Maria Gabriella, Latini, Alessandra, Massimo Giuliani, Morrone, Aldo, Anna Rita Buonomini   +19 more
core   +1 more source